Lv1
80 积分 2022-07-26 加入
Novel Bispecific Degrader BHV-1310 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models including Nonhuman Primates (S18.009)
5天前
已完结
Reshaping the progranulin/sortilin interaction for targeted degradation of extracellular proteins
5天前
已完结
Sorting out extracellular proteins: SORTACs harness sortilin for targeted protein degradation
5天前
已完结
Bifunctional small molecules that mediate the degradation of extracellular proteins
5天前
已完结
Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future
17天前
已完结
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
22天前
已完结
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
22天前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
22天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
22天前
已完结
Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential
22天前
已完结
皖公网安备34019202002308
